Gennova Biopharmaceuticals, based in Pune, India, has received emergency use authorization from the Drugs Controller General of India (DCGI) for its mRNA COVID-19 booster vaccine, GEMCOVAC-OM, targeting the Omicron variant. The vaccine has demonstrated robust immune responses in phase 3 clinical trials conducted across multiple cities in India.
This novel vaccine is considered safe and well tolerated, potentially preventing future waves of the pandemic. The launch of the vaccine is expected in New Delhi within two to three weeks. Individuals aged 18 and older who have already received two doses of either Covaxin or Covishield are eligible to take the booster dose. The vaccine is stable at 2-8 °C and is delivered intradermally using a device called Tropis.
Gennova Biopharmaceuticals is the third company globally and the first in India to develop an mRNA COVID-19 booster vaccine against the highly transmissible Omicron variant. The mRNA platform used in the vaccine allows for the rapid development of vaccines targeting emerging variants.
Subscribe To Our Newsletter
Filter out the noise and nurture your inbox with health and wellness advice that's inclusive and rooted in medical expertise.
Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks
Please update your details